Drug Profile
Aprutumab ixadotin - Bayer
Alternative Names: Abrutumab ixadotine; BAY1187982; FGFR2-ADC - BayerLatest Information Update: 12 Oct 2020
Price :
$50
*
At a glance
- Originator Bayer
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 08 Oct 2020 Seattle Genetics is now called Seagen
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Singapore (IV, Infusion)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in South Korea (IV, Infusion)